GSK’s innovative antiretroviral Single Tablet Regimen Triumeq officially launches in mainland China

GSK today announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare1, was officially launched in mainland China. Triumeq is the first Single Tablet Regimen (STR) for HIV treatment in mainland China which offers Chinese people living with HIV/AIDS the convenience of a single-pill once-a-day regimen.

Triumeq, the only 3-in-1 ARV that contains dolutegravir (DTG), is highly effective and well-tolerated. It poses a high barrier to drug resistance with few drug-drug interactions and can be administered as a single once daily tablet. Triumeq significantly reduces the pill burden on patients, enhances patient drug adherence, and significantly improves their quality of life. 

Triumeq has been approved in 50 countries and regions around the world and has been recommended by many international treatment guideline as the first-line priority therapy for HIV naïve patients.2,3

Professor Fujie Zhang from Beijing Ditan Hospital of Capital Medical University said: ”The ARV treatment is now entering integrase inhibitor (INI) era. Fix dose combination (FDC) has also become the trend of future treatment. INI has shown to be highly effective and well-tolerated. It poses less drug-drug interaction and has a high barrier to drug resistance. Triumeq, as a STR containing a new generation of INI DTG, brings a more convenient treatment with high efficacy to Chinese people living with HIV. It is a big step forward in the current antiviral treatment in China.” 

Thomas Willemsen, General Manager, GSK China Pharmaceuticals and Vaccines, said, “Increasing access to our innovative medicines is a clear strategy for GSK to be in China, with China, for China. We are happy to announce that Triumeq is now available in the Chinese market which provides another innovative treatment solution for people living with HIV. We are working closely with Chinese associations to undertake a series of initiatives, including professional training for HIV/AIDS care personnel, as well as disease prevention and education programmes, to enable Chinese people living with HIV get better support and help”. 

Triumeq’s launch follows the launch of Tivicay, another ARV, by GSK last year. GSK has been providing innovative and high-quality HIV/AIDS treatments to Chinese people living with HIV since 1999, when Combivir was approved as the first drug for the treatment of HIV/AIDS in China. 

As of end of October 2017, the number of known people living with HIV/AIDS patients in China stood at 746,000, with 229,000 cases reported to have died from the condition. 495,000 patients are currently undergoing antiviral therapy.4 

Since 2016, GSK has joined hands with CPMA on the personnel training for HIV/AIDS medical field, and HIV/AIDS disease prevention and education programmes. GSK also works closely with the Home of Red Ribbon in Beijing on the "Care for AIDS Patients" campaign, which called on society to be more caring, understanding, and supportive of people living with HIV and AIDS. GSK has also supported the "Red Ribbon Health Ambassador" campus programme that seeks to create greater awareness of the importance of HIV prevention, especially among young students, in order to control the spread of HIV. The programme was organised by institutions such as the National Health and Family Planning Commission, the Central Committee of the Communist Youth League of China, the State Council Office of AIDS Prevention and Control, and the Chinese Association of STD and AIDS Prevention and Control and held in 16 major universities nationwide.

As part of the ‘in China, with China, for China’ strategy, GSK China has:

  • Supported the launch of “New Respiration and Frequent Care” online management platform for asthma patients in China in December 2017
  • Supported the launch of the UK-China Health and Economy Partnership in November 2017
  • Supported the launch of "Happy Breath", COPD Tiered Diagnosis and Treatment Project across China in November 2017.
  • Announced Flixotide Nebules received approval for the treatment of children asthma in September 2017.
  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in Aug 2017.
  • Announced innovative antiretroviral Single Tablet Regimen Triumeq received approval in mainland China in Aug 2017.
  • Announced Cervarix, first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced the collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Announced Seroxat CR and Tykerb on the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Announced Viread, Arixtra, Requip and Mivacron included in the “2017 National Reimbursement Drug List” in Mar 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in mainland China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.


GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit


GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.


Media enquiries: Susan Song (



  1. ViiV Healthcare, a joint venture in which GSK is the majority shareholder, is a global specialist HIV company.
  2. DHHS Adult/Adolescent Guidelines. updated Apr 6, 2015
  3. Günthard H et al. JAMA 2014; 312:410-25; EACS Guidelines Version 7.1 November 2014
  4. Journal of China HIV/AIDS, Issue 12, No 23, 2017


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.